Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus (SARS-CoV)-2, continues to cause substantial morbidity …

The emergence of novel and evolving variants of SARS-CoV-2 has fostered the need for
change in the form of newer and more adaptive diagnostic methods for the detection of …

Acute respiratory distress syndrome (ARDS) is a common clinical syndrome of acute
respiratory failure as a result of diffuse lung inflammation and oedema. ARDS can be …

Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …

As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …

Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …

Abstract SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has been
associated with substantial global morbidity and mortality. Despite a tropism that is largely …

Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …